Stock 000935700 GILEAD SCIENCES, INC.
Add to a list

Gilead Sciences, Inc. Share Price Berne S.E.

Stocks

000935700

US3755581036

Pharmaceuticals

End-of-day quote Berne S.E.
Other stock markets
 10/02/2026 		5-day change 1st Jan Change
115.86 CHF +69.18% Intraday chart for Gilead Sciences, Inc. +57.76% +69.18%
16/07 Kalshi to allow bets on clinical trials, FDA decisions RE
15/07 African markets - factors to watch on July 15 RE

Valuation: Gilead Sciences, Inc.

Market Cap 17TCr 15TCr 13TCr 12TCr 23TCr 16,05500Cr 24TCr 1,60700Cr 63TCr 7,86300Cr 63TCr 61TCr 27,06900Cr P/E 2026 *
-48.4x
P/E 2027 * 17x
Enterprise Value 18TCr 15TCr 14TCr 13TCr 25TCr 16,96600Cr 25TCr 1,69800Cr 67TCr 8,30900Cr 66TCr 65TCr 28,60500Cr EV / Sales 2026 *
5.78x
EV / Sales 2027 * 5.15x
Free-Float
99.88%
Yield 2026 *
2.42%
Yield 2027 * 2.5%
* Estimated data More valuation ratios

Chart: Gilead Sciences, Inc.

Dynamic Chart

Latest news : Gilead Sciences, Inc.

16/07 Kalshi to allow bets on clinical trials, FDA decisions RE
15/07 African markets - factors to watch on July 15 RE
14/07 Congo begins trial of Gilead's experimental antiviral for Ebola Bundibugyo RE
08/07 Biopharma Companies' Second-Half Performance to be Largely Driven by Fundamentals, Morgan Stanley Says MT
08/07 Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says MT
08/07 Morgan Stanley Adjusts Price Target Gilead Sciences to $166 From $168, Maintains Overweight Rating MT
07/07 Truist Securities Adjusts Gilead Sciences Price Target to $156 From $157 MT
07/07 RBC Capital Adjusts Gilead Sciences Price Target to $120 From $122, Maintains Sector Perform Rating MT
06/07 Analyst recommendations: Chubb, Delta Air Lines, Pfizer, AMD, Dow… Zonebourse
06/07 HSBC Upgrades Gilead Sciences to Buy From Hold, Adjusts Price Target to $155 From $133 MT
03/07 Trial for Ebola treatment starts in DR Congo RE
02/07 Trial for Bundibugyo Ebola treatment starts in DRC, WHO says RE
30/06 Africa CDC seeks $18 million in urgent support for Ebola drug trials in DRC RE
More news

Last Transcript: Gilead Sciences, Inc.

Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 01:20 PM
10/06
More transcripts

Analysts' recommendations: Gilead Sciences, Inc.

08/07 Biopharma Companies' Second-Half Performance to be Largely Driven by Fundamentals, Morgan Stanley Says MT
08/07 Morgan Stanley Adjusts Price Target Gilead Sciences to $166 From $168, Maintains Overweight Rating MT
07/07 Truist Securities Adjusts Gilead Sciences Price Target to $156 From $157 MT
07/07 RBC Capital Adjusts Gilead Sciences Price Target to $120 From $122, Maintains Sector Perform Rating MT
06/07 Analyst recommendations: Chubb, Delta Air Lines, Pfizer, AMD, Dow… Zonebourse
More recommendations

Press Releases: Gilead Sciences, Inc.

02/07 Gilead Sciences : Supports the PARTNERS Trial to Advance Research on Potential Treatments for Ebola Virus Disease PU
25/06 U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer BU
23/06 European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors BU
16/06 U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention AQ
16/06 U.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention BU
More press releases

News in other languages: Gilead Sciences, Inc.

16/06 Warsh betritt die Bühne
16/06 Warsh entra en escena
16/06 Morning Meeting: Der Markt entdeckt seinen Mantel der Unverwundbarkeit wieder
16/06 Bourse : tensions entre Unicredit et l'Allemagne, SpaceX flambe (encore), Bénéteau au régime
16/06 Morning Meeting: El mercado recupera su capa de invencibilidad
More news

Managers and Directors: Gilead Sciences, Inc.

Manager TitleAgeSince
Daniel O'Day CEO
 Chief Executive Officer 61 01/03/2019
Andrew Dickinson DFI
 Director of Finance/CFO 56 01/11/2019
Keeley Wettan CMP
 Compliance Officer - 18/12/2025
Director TitleAgeSince
Kelly Kramer BRD
 Director/Board Member 58 19/08/2016
Jacqueline Barton BRD
 Director/Board Member 73 01/01/2018
Harish Manwani BRD
 Director/Board Member 72 09/05/2018
More insiders

Other Pharmaceuticals

Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5-day change 1-year change 3-year change Capi.($)
GILEAD SCIENCES, INC. Stock Gilead Sciences, Inc.
+69.18%+57.76% - - 17TCr
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+0.85%-0.80%+54.84%+163.70% 1,05100Cr
JOHNSON & JOHNSON Stock Johnson & Johnson
+1.23%-1.53%+55.26%+59.07% 61TCr
ABBVIE INC. Stock AbbVie Inc.
+0.04%+2.58%+32.96%+88.75% 45TCr
ROCHE HOLDING AG Stock Roche Holding AG
+0.78%-0.71%+30.04%+24.61% 33TCr
NOVARTIS AG Stock Novartis AG
+1.41%+0.58%+33.92%+47.20% 28TCr
ASTRAZENECA PLC Stock AstraZeneca PLC
-0.27%-1.87%+22.13%+23.47% 26TCr
NOVO NORDISK A/S Stock Novo Nordisk A/S
-1.76%+2.37%-22.19%-38.45% 22TCr
AMGEN INC. Stock Amgen Inc.
-1.42%+0.80%+22.81%+60.77% 20TCr
PFIZER INC. Stock Pfizer Inc.
-0.36%+3.64%+1.91%-30.15% 14TCr
Average +7.14%+0.56%+25.74%+44.33% 39.46TCr
Weighted average by Cap. +3.45%+0.01%+36.98%+77.39%
See all sector performances

Financials

2026 *2027 *
Net sales 3.05TCr 2.66TCr 2.46TCr 2.26TCr 4.27TCr 2,93400Cr 4.36TCr 29TCr 12TCr 1,43700Cr 11TCr 11TCr 4,94700Cr 3.24TCr 2.83TCr 2.61TCr 2.41TCr 4.54TCr 3,12000Cr 4.64TCr 31TCr 12TCr 1,52800Cr 12TCr 12TCr 5,26000Cr
Net income -339.1Cr -296.34Cr -273.45Cr -252.06Cr -475.08Cr -33TCr -485.62Cr -3.27TCr -1.29TCr -16TCr -1.27TCr -1.25TCr -55TCr 976.18Cr 853.09Cr 787.2Cr 725.61Cr 1.37TCr 94TCr 1.4TCr 9.41TCr 3.7TCr 46TCr 3.67TCr 3.59TCr 1,58500Cr
Net Debt 946.02Cr 826.73Cr 762.88Cr 703.19Cr 1.33TCr 91TCr 1.35TCr 9.12TCr 3.59TCr 45TCr 3.55TCr 3.47TCr 1,53600Cr -
* Estimated data More financial data

Company Profile

Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
-
Sector
Pharmaceuticals
More about the company

Income Statement and Estimates

More financial data

Ratings

Trader

Trader

This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

Investor

Investor

This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

Global

Global

This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.

Quality

Quality

This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.

ESG MSCI

ESG MSCI

The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.

AA
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
134.28USD
Average target price
158.30USD
Spread / Average Target
+17.89%
Consensus
EPS Estimates
Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar
  1. Stock Market
  2. Stocks
  3. GILD Stock
  4. 000935700 Stock

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

MarketScreener
United-States
MarketScreener Canada
Canada

MIDDLE EAST

MarketScreener Saudi Arabia
Saudi Arabia
MarketScreener UAE Emirates
United Arab Emirates

EUROPE

Zonebourse
France
MarketScreener Deutschland
Deutschland
Zonebourse Suisse
Suisse
MarketScreener Schweiz
Schweiz
MarketScreener Italia
Italia
MarketScreener Österreich
Österreich
MarketScreener België
België
MarketScreener Nederland
Nederland
MarketScreener España
España
MarketScreener Sverige
Sverige
MarketScreener UK
United Kingdom

APAC

MarketScreener Australia
Australia
MarketScreener India
India
MarketScreener Hong Kong
Hong Kong